Advertisement

Topics

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

20:00 EDT 1 Oct 2017 | NIH

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic agent that solves this problem facing current chemotherapy treatments. By elegantly exploiting cell surface proteases present at high levels in tumors, they have developed a tumor-targeted anthrax based toxin that inactivates the blood vessels within tumors. While in some cases cancer cells are also killed by the tumor-targeted toxin, the primary mechanism of action is thought to be a decrease in blood flow to the center of tumors, causing cancer cell death and tumor necrosis. Preliminary and on-going studies have demonstrated that the targeted toxins have antitumor effects on melanomas, lung cancers and colon cancer in mouse models, and on feline and canine oral tumors. Interestingly, this therapy does not target a specific type of cancer cell, rather it targets the vasculature in and around tumors. Therefore, it has great potential to treat a wide range of solid tumors. Additionally, because few non-surgical treatments are available to treat many human and veterinary solid tumors, this technology would fill an unmet need in cancer therapy.

IC: 
NIAID
NIH Ref. No.: 
E-256-2015/0
Advantages: 
  • Proven effective in a variety of models, including models of important veterinary cancers
  • Agent is only active in tumor micro-environments, resulting in low toxicity to healthy tissue
  • Cancer cells are not directly targeted, so this agent can be used to treat a broad spectrum of solid tumors and resistance is unlikely to arise
  • Fills an unmet need in cancer therapy, because few non-surgical treatments exist
Applications: 

Therapeutic agent for a wide range of human and veterinary solid tumors, including:

  • Melanomas
  • Lung and colon cancers
  • Oral squamous carcinomas
Provider Technology ID: 
3166
Updated On: 
Feb 27, 2018
Date Published: 
Monday, October 2, 2017
Provider Classifications: 
Publications: 
Patent Application: 
62/210,771
62/323,218
PCT/US2016/048706
15/755,341
Patent Authority: 
US
US
PCT
US
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NIAID
NIAID
NIDCR
Cummings Veterinary Medical Center at Tufts Univer
NHLBI
Emory University
NIAID
Inventor Lab URL: 
http://irp.nih.gov/pi/stephen-leppla
http://irp.nih.gov/pi/thomas-bugge
LPM FIrst Name: 
Wade
LPM Last Name: 
Green
LPM Address: 
BG 5601FL RM 2G56 MSC 9804 5601 FISHERS LN
LPM City: 
Bethesda
LPM Zip: 
20892-9804
Inv Is lead: 
LPM State: 
MD
LPM Phone: 
301-761-7505
LPM Organization: 
NIH Office of Technology Transfer
Pat Filing Date: 
2015-08-27
2016-04-15
2016-08-25
2018-02-26
Publication Link: 
http://www.ncbi.nlm.nih.gov/pubmed/17251181
http://www.ncbi.nlm.nih.gov/pubmed/27357689
http://www.ncbi.nlm.nih.gov/pubmed/26584669
http://www.ncbi.nlm.nih.gov/pubmed/24971906
http://www.ncbi.nlm.nih.gov/pubmed/24434511
http://www.ncbi.nlm.nih.gov/pubmed/22843210
http://www.ncbi.nlm.nih.gov/pubmed/23393143
http://www.ncbi.nlm.nih.gov/pubmed/15895075
Publication Caption: 
PMID 17251181
PMID 27357689
PMID 26584669
PMID 24971906
PMID 24434511
PMID 22843210
PMID 23393143
PMID 15895075
Publication Title: 

Chen KH, et al.

Liu S, et al.

Wein AN, et al.

Peters DE, et al.

Bachran C, et al.

Wein AN, et al.

Phillips DD, et al.

Liu S, et al.

Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize anthrax toxin-based cancer therapeutics. For collaboration opportunities, please contact Dr. Natalie Greco at Natalie.Greco@nih.gov or 301-761-7898.

E Number Only: 
E-256-2015
Inventor First Name: 
Shihui
Stephen
Thomas
Diane
Jie
Alexander
Kuang-Hua
Inventor Last Name: 
Liu
Leppla
Bugge
Guerrero
Liu
Wein
Chen

Original Article: Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

NEXT ARTICLE

More From BioPortfolio on "Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...